

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/094325 A2

- (51) International Patent Classification⁷: **A61K 47/48**
- (21) International Application Number: PCT/EP02/05413
- (22) International Filing Date: 16 May 2002 (16.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
01 112 227.2 18 May 2001 (18.05.2001) EP
- (71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; 55216 Ingelheim/Rhein (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ADOLF, Günther** [AT/AT]; Stiftgasse 15-17/10, A-1070 Wien (AT). **HEIDER, Karl-Heinz** [DE/AT]; Johann-Strauss-Promenade 4/11, A-2000 Stockerau (AT). **PATZELT, Erik** [AT/AT]; Hans Buchmueller-Gasse 8, A-3002 Punksdorf (AT). **SPROLL, Marlies** [DE/DE]; Munchenerstr. 32a, 82131 Gauting (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/094325 A2

(54) Title: CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES

(57) Abstract: The present invention relates to novel conjugates of antibodies with cytotoxic compounds, pharmaceutical compositions containing such conjugates, and their use in cancer therapy. In particular, the present invention relates to conjugates of antibodies which are specific for CD44 with maytansinoids, preferably with N²-deacetyl-N² (3-mercapto-1-oxopropyl)-maytansine (DM1).

Cytotoxic CD44 Antibody Immunoconjugates

The invention relates to novel conjugates of antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.

5

There have been numerous attempts to improve the efficacy of antineoplastic drugs by conjugating such drugs to antibodies against tumor-associated antigens in order to elevate local concentration of the drug by targeted delivery to the tumor. Many of these approaches have met limited success, and several reasons have been discussed in the literature to explain the failure. For anticancer drugs acting stoichiometrically, like e.g. doxorubicin or methotrexate, relatively high intracellular concentrations are necessary to exert the required cytotoxicity. These concentrations are thought to be difficult to achieve with many antibody-drug conjugates because of (a) insufficient potency of many common anticancer drugs, (b) low cell surface concentration of antigen targets, (c) inefficient internalization of antigen-antibody complexes into the target cell, and (d) inefficient release of free drug from the conjugate inside the target cell (Chari et al., 1992).

Two of the aforementioned drawbacks, namely (a) and (d), have been addressed by the work of Chari and coworkers (Chari et al., 1992; Liu et al., 1996; U.S. Patent No. 5,208,020). They have developed antibody conjugates wherein the antibody is linked to a maytansinoid via a disulfide linkage. Maytansines belong to the class of Ansa macrolide antibiotics, which derive from *Nocardia* sp.. The maytansine ansamitocin P-3, produced by bacterial fermentation, is used as a precursor molecule to manufacture maytansinoid DM1. Maytansine and derivatives act as anti-mitotic agents (inhibitors of tubulin polymerization), similar as vincristine, but with markedly higher potency than vincristine or other established chemotherapeutic agents (DM1 is toxic to cells *in vitro* at $\sim 10^{-10}$ M concentration). In contrast to the high cytotoxicity of free maytansinoid, the antibody conjugate has a toxicity which is several orders of magnitude lower on antigen-negative cells compared to antigen-positive cells. The linkage by disulfide bonding has the advantage that these bonds are readily cleaved inside the target cells by intracellular glutathione, releasing highly toxic free drug. This approach has been applied to antibodies against tumor-associated antigens, for example the C242-DM1 conjugate (Liu et al., 1996; Lambert et al., 1998), and HuN901-DM1 (Chari et al., 2000). However, the application of

30

CONFIRMATION COPY

these conjugates is restricted due to the limited expression of the respective target antigens. For example, the antigen recognized by N901 (CD56, N-CAM) is predominantly expressed by tumors of neuroendocrine origin, the expression of the C242 antigen (CanAg) is mostly limited to tumors derived from the GI tract.

5

There is, however, still the need to improve this approach by finding suitable tumor-associated antibodies with favorable antigen expression pattern, high and specific cell surface antigen concentration within the target tissue, and efficient internalization process transporting the antigen complexed-antibody conjugate into the cells.

10

CD44 is a protein which is expressed in several different isoforms on the surface of a wide variety of cell types. The smallest isoform, standard CD44 (CD44s), which is expressed by a variety of different cells, is thought to mediate cell attachment to extracellular matrix components and may transmit a co-stimulus in lymphocyte and monocyte activation. In contrast, expression of splice variants of CD44 which contain the domain v6 (CD44v6) in the extracellular region, is restricted to a subset of epithelia. The physiological role of CD44v6 is not yet fully understood.

15

CD44v6, as well as other variant exons (CD44v3, CD44v5, CD44v7/v8, CD44v10) has been shown to be a tumor-associated antigen with a favorable expression pattern in human tumors and normal tissues (Heider et al., 1995; Heider et al., 1996; Dall et al., 1996; Beham-Schmid et al., 1998; Tempfer et al., 1998; Wagner et al., 1998) and has been subject to antibody-based diagnostic and therapeutic approaches, in particular radioimmunotherapy (RIT) of tumors (Verel *et al.*, 2002; Stromer et al., 2000; WO 95/33771; WO 97/21104).

20

However, a prerequisite for efficient killing of tumor cells by antibody maytansinoid conjugates is sufficient internalization of the target antigen. Only few data on the internalization of CD44 are available. Bazil et Horejsi reported that downregulation of CD44 on leukocytes upon stimulation with PMA is caused by shedding of the antigen rather than by internalization (Bazil et Horejsi, 1992). Shedding of CD44 is also supported by several reports on soluble CD44 in the serum of tumor patients and normal individuals (Sliutz et al., 1995; Guo et al., 1994; Martin et al., 1997). In a recent paper by Aguiar et al.

30

the amount of internalized CD44 on matrix-intact chondrocytes was determined to be approximately 6% in 4 hours (Aguiar et al., 1999). Similar low levels of internalized CD44v6 on tumor cells were found in experiments performed by BIA. Taken together, these data suggest that CD44 receptors are more likely subject to shedding than to internalization, and thus CD44 specific antibodies are not to be regarded as suitable candidates for the maytansinoid conjugate approach. This has been supported by in vitro cell proliferation assays wherein Ab_{CD44v6}-DM1 showed only slightly elevated cytotoxicity against antigen-presenting cells as compared to cells lacking the antigen.

10 It now has been unexpectedly found that CD44 specific antibodies conjugated to highly cytotoxic drugs through a linker which is cleaved under intracellular conditions are very efficient tumor therapeutics in vivo.

The present invention provides novel compounds consisting of a CD44 specific antibody molecule conjugated to a highly cytotoxic drug through a linker which is cleaved under intracellular conditions.

In particular, the present invention provides a compound of formula

A(LB)_n (Formula (I))

20 wherein

A is an antibody molecule which is specific for CD44;

L is a linker moiety;

B is a compound which is toxic to cells; and

n is a decimal number with $n = 1$ to 10

25

The antibody molecule A has a binding specificity for CD44, preferably variant CD44.

The term „antibody molecule“ shall encompass complete immunoglobulins as they are produced by lymphocytes and for example present in blood sera, monoclonal antibodies secreted by hybridoma cell lines, polypeptides produced by recombinant expression in host cells which have the binding specificity of immunoglobulins or monoclonal antibodies, and molecules which have been derived from such immunoglobulins, monoclonal antibodies, or polypeptides by further processing while retaining their binding specificity. In particular,

the term „antibody molecule“ includes complete immunoglobulins comprising two heavy chains and two light chains, fragments of such immunoglobulins like Fab, Fab', or F(ab)₂ fragments (Kreitman *et al.*, 1993), recombinantly produced polypeptides like chimeric, humanised or fully human antibodies (Breitling *et al.*, 1999; Shin *et al.*, 1989; Güssow *et al.*, 1991, Winter *et al.*, 1994, EP 0 239 400; EP 0 519 596; WO 90/07861 EP 0 368 684; EP 0 438 310; WO 92/07075; WO 92/22653; EP 0 680 040; EP 0 451 216), single chain antibodies (scFv, Johnson *et al.*, 1991), and the like. Today, antibodies may also be produced without immunising a laboratory animal, e.g. by phage display methods (Aujame *et al.*, 1997; US 5,885,793; US 5,969,108; US 6,300,064; US 6,248,516, US 6,291,158). Fully human antibodies may be produced using transgenic mice carrying functional human Ig genes (EP 0 438 474 ; EP 0 463 151; EP 0 546 073). From the aforementioned literature references, the expert knows how to produce these types of antibody molecules, employing state of the art methods like automated peptide and nucleic acid synthesis, laboratory animal immunisation, hybridoma technologies, polymerase chain reaction (PCR), vector and expression technologies, host cell culture, and protein purification methods. In the following, the terms „antibody“ and „antibody molecule“ are used interchangeably.

„Specific for CD44“ shall mean that the antibody molecule has specific binding affinity for an epitope present in CD44. In a preferred embodiment, the antibody molecule of the invention has a binding specificity for the amino acid sequence coded by variant exon v6 of the human CD44 gene. The sequence of variant exon v6 as well as of the other variant exons is known in the art (Screaton *et al.*, 1992; Tölg *et al.*, 1993; Hofmann *et al.*, 1991). A preferred antibody molecule of the invention specifically binds to peptides or polypeptides having or containing the amino acid sequence SEQ ID NO: 1 of the accompanying sequence listing, or an allelic variant of said sequence. Preferably, said antibody molecule has binding specificity for an epitope within said sequence. More preferably, the antibody molecule specifically binds to a peptide having the amino acid sequence SEQ ID NO: 2, even more preferably having the amino acid sequence SEQ ID NO: 3. Such antibody molecules may be easily produced with methods known in the art (WO 95/33771, WO 97/21104), e.g. by immunising laboratory animals with chemically synthesised peptides having the aforementioned sequences, e.g. bound to a hapten, or immunising with a recombinantly produced fusion protein including said sequences, and proceeding according

to methods known in the art (Harlow 1988; Catty 1988; Koopman *et al.*, 1993; Heider *et al.*, 1993).

Preferably, an antibody molecule according to the invention is the murine monoclonal
5 antibody with the designation VFF-18 which is produced by a hybridoma cell line which
has been deposited on 07 June 1994 under the accession number DSM ACC2174 with the
DSM-Deutsche Sammlung für Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 1b, D-38124 Braunschweig, Deutschland/Germany. Also preferred are Fab, Fab', or
F(ab)₂ fragments of said monoclonal antibody VFF-18. In another preferred embodiment,
10 the antibody molecule is a humanised recombinant antibody, wherein the complementarity
determining regions (CDR's) of VFF-18 have been grafted into the respective genes of
human immunoglobulin heavy and light chains.

"Complementarity determining regions" of a monoclonal antibody are understood to be
15 those amino acid sequences involved in specific antigen binding according to Kabat *et al.*,
1991, in connection with Chothia and Lesk, 1987.

In another preferred embodiment, appropriate framework residues of such a CDR-grafted
antibody are reverted to murine residues to improve binding affinity. From methods
20 pertinent to the art, the experts knows how to obtain the CDR's of VFF-18, starting with
the aforementioned hybridoma with the accession number DSM ACC2174, to choose and
obtain appropriate human immunoglobulin genes, to graft the CDR's into these genes, to
modify selected framework residues, to express the CDR-grafted antibody in appropriate
host cells, e.g. Chinese hamster ovary (CHO) cells, and to test the resulting recombinant
25 antibodies for binding affinity and specificity (see e.g. literature references above). In
another preferred embodiment of the invention, the antibody molecule is a recombinant
antibody having the CDR's of the antibody VFF-18. Preferably, such a recombinant
antibody is a humanised antibody and is a complete immunoglobulin consisting of two
complete light and two complete heavy chains. In another preferred embodiment of the
30 invention, the antibody molecule is a recombinant antibody having the same idiotype as the
antibody VFF-18. In another preferred embodiment of the invention, the antibody molecule
is a recombinant antibody binding to the same epitope as the antibody VFF-18.

In a particular preferred embodiment, the antibody molecule A is an antibody comprising light chains having the amino acid sequence SEQ ID NO: 4, and heavy chains having the amino acid sequence SEQ ID NO: 6. This antibody is called BIWA 4. It is a humanised version of antibody VFF-18 mentioned above, having the complementary determining
5 regions of the murine monoclonal antibody VFF-18 in a completely human framework, and human constant regions. It is therefore an antibody of very low immunogenicity in man, which is a favorable trait. However, as it has no murine framework residues to optimise antigen binding, it has a significantly lower antigen binding affinity as its parent antibody VFF-18, and therefore would not have been regarded as a good candidate for a therapeutic
10 drug. Unexpectedly, it has been found that BIWA 4, despite its poor binding affinity, has a very favorable biodistribution and tumor uptake in vivo, making it superior to other humanised versions of VFF-18 with higher binding affinity (Verel *et al.*, 2002). In a further preferred embodiment, the antibody molecule A is an antibody comprising light chains having the amino acid sequence SEQ ID NO: 8, and heavy chains having amino acid
15 sequence SEQ ID NO: 6. This antibody has higher binding affinity than BIWA 4 and is called BIWA 8.

These antibodies may be produced as follows. Nucleic acid molecules coding for the light chain and the heavy chain may be synthesised chemically and enzymatically by standard
20 methods. First, suitable oligonucleotides can be synthesized with methods known in the art (e.g. Gait, 1984), which can be used to produce a synthetic gene. Methods to generate synthetic genes from oligonucleotides are known in the art (e.g. Stemmer *et al.* 1995; Ye *et al.* 1992; Hayden *et al.* 1988; Frank *et al.* 1987). Preferably, the nucleic acid molecules encoding the light and heavy chains of BIWA 4 have the nucleotide sequences
25 of SEQ ID NO: 5 and SEQ ID NO: 7, respectively. These sequences include sequences coding for leader peptides which are cleaved by the host cell (SEQ ID NO: 5: the first 60 nucleotides; SEQ ID NO: 7: the first 57 nucleotides). In a further embodiment, the nucleic acid molecules encoding the light and heavy chains of an antibody molecule according to the invention have the nucleotide sequences of SEQ ID NO: 9 and SEQ ID NO: 7,
30 respectively. These nucleic acid molecules encoding the antibody heavy and light chains then may be cloned into an expression vector (either both chains in one vector molecule, or each chain into a separate vector molecule), which then is introduced into a host cell. Expression vectors suitable for immunoglobulin expression in prokaryotic or eukaryotic

host cells and methods of introduction of vectors into host cells are well-known in the art. In general, the immunoglobulin gene therein is in functional connection with a suitable promoter, like for example a human cytomegalovirus (CMV) promoter, hamster ubiquitin promoter (WO 97/15664), or a simian virus SV40 promoter located upstream of the Ig

5 gene. For termination of transcription, a suitable termination/polyadenylation site like that of the bovine growth hormone or SV40 may be employed. Furthermore, an enhancer sequence may be included, like the CMV or SV40 enhancer. Usually, the expression vector furthermore contains selection marker genes like the dihydrofolate reductase (DHFR), glutamine synthetase, adenosine deaminase, adenylate deaminase genes, or the neomycin,

10 bleomycin, or puromycin resistance genes. A variety of expression vectors are commercially available from companies such as Stratagene, La Jolla, CA; Invitrogen, Carlsbad, CA; Promega, Madison, WI or BD Biosciences Clontech, Palo Alto, CA. For example, expression vectors pAD-CMV1 (NCBI GenBank Accession No. A32111) or pAD-CMV19 (NCBI GenBank Accession No. A32110) may be used for expression.. The

15 host cell preferably is a mamalian host cell, e.g. a COS, CHO, or BHK cell, more preferably a chinese hamster ovary (CHO) cell, e.g. a CHO-DUKX (Urlaub and Chasin, 1980), CHO-DG44 (Urlaub et al., 1983), or CHO-K1 (ATCC CCL-61) cell. The host cell then is cultured in a suitable culture medium under conditions where the antibody is produced, and the antibody is then isolated from the culture according to standard

20 procedures. Procedures for production of antibodies from recombinant DNA in host cells and respective expression vectors are well-known in the art (see e.g. WO 94/11523, WO 97/9351, EP 0 481 790, EP 0 669 986).

In order to link the antibody molecule A to the compound B which is toxic to cells, a

25 linking moiety L is used. In the most simple case, the linking moiety L is a chemical bond, preferably a covalent bond which is cleaved under intracellular conditions. In one embodiment of the invention, the bond is between a sulfur atom present in the antibody molecule, e.g. in the side chain of a cystein residue, and another sulfur atom present in the toxic compound. In another embodiment, the linking moiety L consists of one or more

30 atoms or chemical groups. Suitable linking groups are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups. Preferred are disulfide groups and thioether groups.

Conjugates of the antibody molecules of the invention and toxic compound can be formed using any techniques presently known or later developed. The toxic compound can be modified to yield a free amino group and then linked to the antibody molecule via an acid-labile linker, or a photolabile linker. The toxic compound can be condensed with a peptide and subsequently linked to an antibody molecule to produce a peptidase-labile linker. The toxic compound can be treated to yield a primary hydroxyl group, which can be succinylated and linked to an antibody molecule to produce a conjugate that can be cleaved by intracellular esterases to liberate free drug. Most preferably, the toxic compound is treated to create a free or protected thiol group, and then one or many disulfide or thiol-containing toxic compounds are covalently linked to the antibody molecule via disulfide bond(s).


For example, antibody molecules can be modified with crosslinking reagents such as N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), 4-succinimidyl-oxycarbonyl- α -methyl- α -(2-pyridyldithio)-toluene (SMPT), N-succinimidyl-3-(2-pyridyldithio)-butyrate (SDPB), N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-5-(2-pyridyldithio)pentanoate, 2-iminothiolane, or acetylsuccinic anhydride by known methods. See, Carlsson et al, 1978; Blattler et al 1985; Lambert et al, 1983; Klotz et al, 1962; Liu et al, 1979; Blakey and Thorpe, 1988; Worrell et al, 1986. In a preferred embodiment, the linker moiety is a 4-thiopentanoate derived from SPP, or 5-thiopentanoate. The antibody molecule containing free or protected thiol groups thus derived is then reacted with a disulfide- or thiol-containing toxic compound to produce conjugates. The conjugates can be purified by HPLC or by gel filtration.

„Toxic“ is a compound that inhibits or prevents function of cells and/or causes cell destruction. Toxic compounds used for coupling may act either cytostatic or cytotoxic and lead to cell cycle arrest or cell death. These compounds may act at different stages during the cell cycle, e.g. by interference with nucleic acid synthesis, inactivation of nucleic acids, or by binding to tubulin.

In a preferred embodiment, the compound B which is toxic to cells is a maytansinoid, i.e. a derivative of maytansine (CAS 35846538). In a preferred embodiment, it is a C-3 ester of maytansinol. Maytansinoids suitable for conjugating to antibodies for use in cancer

therapy, including preparation of said maytansinoids and their linkage to antibody molecules, have been described by Chari and Coworkers (Chari et al., 1992; Liu et al., 1996; U.S. Patent No. 5,208,020). These maytansinoids may be used for the present invention. In a preferred embodiment, the toxic compound is N^{2'}-deacetyl- N^{2'}-(3-mercapto-1-oxopropyl)-Maytansine (CAS Number 139504-50-0), also referred to as DM1. Preferably, said maytansinoid is a maytansinol derivative linked to the antibody molecule via a disulfide bridge at the C-3 position of maytansinol. In a particularly preferred embodiment, the antibody/maytansinoid conjugate may be prepared from a maytansinoid of formula

Formula (II)




wherein

- 15 R_1 represents H or SR_4 , wherein R_4 represents methyl, ethyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl, or heterocyclic;
- R_2 represents Cl or H;
- R_3 represents H or CH_3 ; and
- m represents 1, 2, or 3.
- 20 Preferably, R_1 is H, CH_3 , or SCH_3 , R_2 is Cl, R_3 is CH_3 , and $m = 2$.

The compound with $R_1 = H$, $R_2 = Cl$, $R_3 = CH_3$, and $m = 2$ is designated DM1 in the literature.

In a preferred embodiment, the compound of the invention has the formula

5



10

(Formula III)

wherein

A is an antibody molecule which is specific for CD44, preferably specific for the variant exon v6, preferably specific for the amino acid sequence SEQ ID NO: 3;

15

(L') is an optional linker moiety


p is a decimal number with $p = 1$ to 10.

Preferably, p is 3 to 4, more preferably about 3.5.

20

Methods for preparing such maytansinoids are known in the art (see in particular US 5,208,020, Example 1). Conveniently, in a first step the maytansinoid C-3 ester ansamitocin P3 may be produced by bacterial fermentation of microorganisms belonging to the genus *Nocardia* or *Actinosynnema*, e.g. ATCC 31565, ATCC 31281 (US 4,356,265;

US 4,450,234; WO 01/77360). Ansamitocin P3 may be extracted from the culture using organic solvents like ethyl acetate or toluene, and further purified by adsorption chromatography using e.g. silica gel. It may then be reduced to maytansinol using LiAlH_4 (US 4,360,462) or, as suggested more recently, $\text{LiAl(OMe)}_3\text{H}$ or other LiAl or NaAl hydrides (WO 02/16368). The maytansinol may then be esterified at the C-3 position with N-methyl-L-alanine or N-methyl-L-cysteine derivatives to yield a disulfide-containing maytansinoid (US 5,208,020; US 5,416,064; US 6,333,410), for example using dicyclohexylcarbodiimide(DCC) and catalytic amounts of zinc chloride (US 4,137,230; US 4,260,609). In a preferred embodiment, the maytansinol is esterified with the compound N-methyl-N-(3-methyldithiopropionyl)-L-alanine of formula



to yield the maytansinoid of Formula (II) with $\text{R}_1 = \text{SR}_4$, $\text{R}_4 = \text{CH}_3$, $\text{R}_2 = \text{Cl}$, $\text{R}_3 = \text{CH}_3$, and $m = 2$.

15

The free thiol group may then be released by cleavage of the disulfide bond with dithiothreitol (DTT), to yield e.g. DM1.

Upon intracellular cleavage, the free toxic compound is released from the conjugate A(LB)_n . The free drug released from the compound A(LB)_n may have the formula B-X , wherein X is an atom or a chemical group, depending on the nature of the cleaving reaction. Preferably, X is a hydrogen atom, as for example when the linker moiety is just a covalent bond between two sulfur atoms, or a hydroxyl group. The cleavage site may also be within the linker moiety if the linker moiety is a chemical group, generating free drug of formula B-L''-X upon cleavage, wherein X is an atom or a chemical group, depending on the nature of the cleaving reaction. Preferably, X is a hydrogen atom or a hydroxyl group.

In a preferred embodiment, the compound of formula (I) is less toxic than the toxic compound B, B-X or B-L''-X released upon intracellular cleavage. Methods of testing cytotoxicity in vitro are known in the art (Goldmacher et al., 1985; Goldmacher et al.,

30

1986; see also US 5,208,020, Example 2). Preferably, the compound (I) is 10 times or more, more preferably 100 times or more, or even 1000 times or more less toxic than the free drug released upon cleavage.

- 5 Preferably, antibody molecule/maytansinoid conjugates are those that are joined via a disulfide bond, as discussed above, that are capable of delivering maytansinoid molecules. Such cell binding conjugates are prepared by known methods such as modifying monoclonal antibodies with succinimidyl pyridyl-dithiopropionate (SPDP) or pentanoate (SPP) (Carlsson et al, 1978). The resulting thiopyridyl group is then displaced by treatment
10 with thiol-containing maytansinoids to produce disulfide linked conjugates. Alternatively, in the case of the arylthiomaytansinoids, the formation of the antibody conjugate is effected by direct displacement of the aryl-thiol of the maytansinoid by sulfhydryl groups previously introduced into antibody molecules. Conjugates containing 1 to 10 maytansinoid drugs linked via a disulfide bridge are readily prepared by either method. In
15 this context, it is understood that the decimal number n in the formula $A(LB)_n$ is an average number as not all conjugate molecules of a given preparation may have the identical integer of LB residues attached to the antibody molecule.

More specifically, a solution of the dithiopyridyl modified antibody at a concentration of 1
20 mg/ml in 0.1M potassium phosphate buffer, at pH 7.0 containing 1 mM EDTA is treated with the thiol-containing maytansinoid (1.25 molar equivalent/dithiopyridyl group). The release of pyridine-2-thione from the modified antibody is monitored spectrophotometrically at 343nm and is complete in about 30 min. The antibody-maytansinoid conjugate is purified and freed of unreacted drug and other low molecular
25 weight material by gel filtration through a column of Sephadex G-25. The number of maytansinoids bound per antibody molecule can be determined by measuring the ratio of the absorbance at 252 nm and 280 nm. An average of 1-10 maytansinoid molecules/antibody molecule can be linked via disulfide bonds by this method.


- 30 In a further aspect, the present invention relates to a conjugate of a CD44v6 specific antibody molecule and a maytansinoid. Herein, „CD44v6 specific“ shall mean that the antibody has specific binding affinity to an epitope which is present in a peptide having the amino acid sequence encoded by variant exon v6 of CD44, preferably human CD44. A

preferred antibody molecule of the invention specifically binds to peptides or polypeptides having or containing the amino acid sequence SEQ ID NO: 1 of the accompanying sequence listing, or an allelic variant of said sequence. Preferably, said antibody molecule has binding specificity for an epitope within said sequence. More preferably, the antibody molecule specifically binds to a peptide having the amino acid sequence SEQ ID NO: 2,
 5 even more preferably having the amino acid sequence SEQ ID NO: 3.

Preferably, the antibody molecule in said conjugate is the monoclonal antibody VFF-18 (DSM ACC2174) or a recombinant antibody having the complementary determining regions (CDRs) of VFF-18. More preferably, the said antibody comprises light chains
 10 having the amino acid sequence SEQ ID NO: 4, or, alternatively, SEQ ID NO: 8, and heavy chains having the amino acid sequence SEQ ID NO: 6.

The maytansinoid is preferably linked to the antibody by a disulfide moiety and has the
 15 formula

Formula (IV)




wherein the link to the antibody is through the sulfur atom shown in formula IV to a second
 20 sulfur atom present in the antibody molecule. To create such a sulfur atom available for bonding, an antibody molecule may be modified by introduction of a suitable linker as

outlined above. Preferably, the maytansinoid is linked to the antibody molecule through a –S-CH₂CH₂-CO-, a –S-CH₂CH₂CH₂CH₂-CO-, or a –S-CH(CH₃)CH₂CH₂-CO- group. The sulfur atom in such a linker group forms the disulfide bond with the maytansinoid, while the carbonyl function may be bonded to an amino function present on the side chain of an amino acid residue of the antibody molecule.

That way, one or more maytansinoid residues may be linked to an antibody molecule. Preferably, 3 to 4 maytansinoid residues are linked to an antibody molecule.

- Most preferred is a conjugate of a CD44v6 specific antibody molecule and a maytansinoid, wherein the antibody comprises light chains having the amino acid sequence SEQ ID NO: 4, and heavy chains having the amino acid sequence SEQ ID NO: 6, and wherein the maytansinoid has the formula



(Formula IV)

and is linked to the antibody through a disulfide bond. Preferably, the linking group is –S-CH₂CH₂CH₂CH₂-CO- or –S-CH(CH₃)CH₂CH₂-CO-, and the number of maytansinoid residues bound per antibody molecule is 3 to 4.

In a further embodiment, the present invention relates to a method of production of a compound of formula (I) comprising the steps:

- 5 (a) introducing free or protected thiol groups into an antibody molecule which is specific for CD44;
 - (b) reacting the antibody molecule of step (a) with a compound which is toxic to cells, said compound having one or more disulfide or thiol groups; and
 - (c) recovering the resulting conjugate.
- 10 Preferably, the antibody molecule is specific for CD44v6, more preferably specific for the amino acid sequence SEQ ID NO: 3. The compound which is toxic to cells is preferably a maytansinoid, more preferably of formula (II), most preferably with $R_1 = H$, $R_2 = Cl$, $R_3 = CH_3$, and $m = 2$. In a further preferred embodiment, the antibody comprises light chains having the amino acid sequence SEQ ID NO: 4 or SEQ ID NO: 8, and heavy chains having
- 15 the amino acid sequence SEQ ID NO: 6.

In preferred embodiments of such a method, (2-pyridyl)-3-dithiopropionic acid N-hydroxy succinimid ester (N-succinimidyl-3-(2-pyridyldithio)-propionate), (2-pyridyl)-4-dithiopentanoic acid N-hydroxy succinimid ester (N-succinimidyl-4-(2-pyridyldithio)-

20 pentanoate), or (2-pyridyl)-5-dithiopentanoic acid N-hydroxy succinimid ester (N-succinimidyl-5-(2-pyridyldithio)-pentanoate) are used to introduce the free or protected thiol groups into the antibody molecule. The invention also relates to compounds obtainable by a method as described.

- 25 In a further embodiment, the present invention relates to a pharmaceutical composition comprising a compound of formula (I), or a conjugate as described, preferably together with a pharmaceutically acceptable carrier, excipient, or diluent.

Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and

30 can be determined by those of skill in the art as the clinical situation warrants. Examples of suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose.

More preferably, the antibody molecule present in the pharmaceutical composition is the monoclonal antibody VFF-18, or a recombinant antibody having the CDR's of the antibody VFF-18, preferably in a human framework. In a further preferred embodiment, the antibody
5 comprises light chains having the amino acid sequence SEQ ID NO: 4 or SEQ ID NO: 8, and heavy chains having the amino acid sequence SEQ ID NO: 6. Preferably, the toxic compound is the maytansinoid of formula (II).

The compounds of the invention may be used for all kinds of clinical or non-clinical
10 applications wherein a toxic compound is to be targeted to cells expressing CD44, preferably CD44v6 on the cell surface.

The conjugate may for example be clinically used ex vivo to remove tumor cells from bone marrow prior to autologous transplantation in cancer treatment. Treatment can be carried
15 out as follows. Bone marrow is harvested from the patient or other individual and then incubated in medium containing serum to which is added the compound of formula (I) according to the invention, concentrations range from about 10 μ M to 1 pM, for about 30 minutes to about 48 hours at about 37°C. The exact conditions of concentration and time of incubation (=dose) are readily determined by the skilled artisan. After incubation, the bone
20 marrow cells are washed with medium containing serum and returned to the patient by i.v. infusion according to known methods. In circumstances where the patient receives other treatment such as a course of ablative chemotherapy or total-body irradiation between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.

25 In a further embodiment, the present invention relates to a method of treatment of cancer comprising applying a pharmaceutical composition as described before to a patient. In particular, this aspect of the invention relates to a method of treatment of cancer in a patient in need thereof comprising administering to the patient a therapeutically effective
30 amount of a compound as described above, or a pharmaceutical composition as described above. Preferably, the cancer is head and neck squamous cell carcinoma (SCC), esophagus SCC, lung SCC, skin SCC, breast adenocarcinoma (AC), lung AC, cervix SCC, pancreas AC, colon AC, or stomach AC.

For clinical treatment of cancer, the compound of formula (I) according to the invention will be supplied as solutions that are tested for sterility and for endotoxin levels. Examples of suitable protocols of conjugate administration are as follows. Conjugates may be given weekly for 1 to 6 weeks either as an i.v. bolus, or as a continuous infusion for 5 days. Bolus doses can be given in 50 to 100 ml of normal saline to which 5 to 10 ml of human serum albumin has been added. Continuous infusions can be given in 250 to 500 ml of normal saline, to which 25 to 50 ml of human serum albumin has been added, per 24 hour period. Dosages will generally be 10 mg to 400 mg/m² of body surface area per application. The dose applied to the patient per administration has to be high enough to be effective, but must be below the dose limiting toxicity (DLT). In general, a sufficiently well tolerated dose below DLT will be considered maximum tolerated dose (MTD). The expert knows how to determine the MTD (Lambert et al., 1998). For weekly administrations, the MTD can be expected to be in the range of 100 to 200 mg/m². Alternatively, intervals between applications may be longer, e.g. two to four weeks, preferably three weeks. In this case, the MTD can be expected to be in the range of 200 to 300 mg/m². Alternatively, application may be in 5 daily doses, followed by a break of several weeks after which treatment may be repeated. In this case, the MTD per administration can be expected to be lower than 100 mg/m². For example, conjugates can be administered as a single i.v. infusion with a rate of 3 mg/min every 21 days. Up to 7 cycles of treatment were applied. It is to be understood that the applied doses may well be out of the ranges given above if the clinical situation requires. For example, if the MTD is found to be higher than indicated, single administration may be at a higher dose than 400 mg/m², or weekly may be at more than 200 mg/m².

Dose, route of administration, application scheme, repetition and duration of treatment will in general depend on the nature of the disease (type, grade, and stage of the tumor etc.) and the patient (constitution, age, gender etc.), and will be determined by the medical expert responsible for the treatment. Besides treatment of solid tumors, therapeutic application according to the invention may be particularly advantageous as an adjuvant to surgical intervention, to treat minimal residual disease.

In a further embodiment, the invention relates to the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of cancer. More preferably, the antibody molecule present in the pharmaceutical composition is the monoclonal antibody VFF-18, or a recombinant antibody having the CDR's of the antibody VFF-18, preferably in a human framework. Most preferred is an antibody molecule comprising a light chain having SEQ ID NO: 4 or SEQ ID NO: 8, and a heavy chain having SEQ ID NO: 6. Preferably, the toxic compound has the formula (II). Preferably, the cancer is head and neck squamous cell carcinoma (SCC), esophagus SCC, lung SCC, skin SCC, breast adenocarcinoma (AC), lung AC, cervix SCC, pancreas AC, colon AC, or stomach AC.

References

- Aguiar DJ, Knudson W, and Knudson CB. Internalization of the hyaluronan receptor CD44 by chondrocytes. *Exp.Cell.Res.* 252: 292-302, 1999.
- Aujame L, Geoffroy F, Sodoyer R. High affinity human antibodies by phage display. *Hum Antibodies* 8(4):155-68 (1997).
- Bazil V and Horejsi V. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. *J Immunol* 149 (3):747-753, 1992.
- Blattler et al, *Biochem.* 24: 1517-1524 (1985).
- Breitling F, Duebel S: *Recombinant Antibodies*. John Wiley, New York 1999.
- Carlsson et al, *Biochem. J.* 173: 723-737 (1978).
- Catty D. *Antibodies*. Oxford IR Press 1988.

Chari RVJ, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. *Cancer Research* 52: 127-31, 1992.

- 5 Chari RVJ, Derr SM, Steeves RM, Widdison WC: Dose-response of the anti-tumor effect of HUN901-DM1 against human small cell lung cancer xenografts. *Proceedings of the American Association of Cancer Research* (2000) 41(April 1-5) Abs 4405.

Chothia and Lesk. *J. Mol. Biol.* 196: 901-917 (1987).

10

Frank et al. *Methods Enzymol.* 154: 221-249 (1984)

Gait, M.J., *Oligonucleotide Synthesis. A Practical Approach.* IRL Press, Oxford, UK (1984).

15

Goldmacher et al., *J Immunol* 135: 3648-3651, 1985.

Goldmacher et al., *J Cell Biol* 102: 1312-1319, 1986.

- 20 Güssow D, Seemann G. Humanization of monoclonal antibodies. *Methods Enzymol.* 203: 99-121 (1991)

- Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, and Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. *Cancer Res* 54 (2): 422-426, 1994.

25

Harlow L D. *Antibodies.* Cold Spring Harbor Lab. 1988

- Hayden et Mandecki. Gene synthesis by serial cloning of oligonucleotides. *DNA* 7(8): 571-7 (1988).

30

Heider, K.-H., Hofmann, M., Horst, E., van den Berg, F., Ponta, H., Herrlich, P., and Pals, S.T. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. *J. Cell Biol.* 120: 227-233 (1993).

- 5 Heider KH, Mulder JWR, Ostermann E, Susani S, Patzelt E, Pals ST, Adolf GRA. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor cells are expressed in normal tissues of humans and cynomolgus monkeys. *Eur. J. Cancer* 31A: 2385-2391, 1995.
- 10 Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann O, Ahorn H, Adolf GRA. Characterization of a high affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. *Cancer Immunology Immunotherapy* 43: 245-253, 1996.
- 15 Hofmann, M., Rudy, W., Zöller, M., Tölg, C., Ponta, H., Herrlich P., and Günthert, U. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. *Cancer Res.* 51: 5292-5297 (1991).
- 20 Johnson S, Bird R E. Construction of single-chain derivatives of monoclonal antibodies and their production in *Escherichia coli*. *Methods Enzymol.* 203: 88-98 (1991).
- Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S. and Foeller C. Sequences of Proteins of Immunological Interest (5th Ed.). NIH Publication No. 91-3242. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD (1991).
- 25 Klotz et al, *Arch. Biochem. Biophys.* 96: 605 (1962).
- Koopman, G., Heider, K.-H., Horts, E., Adolf, G. R., van den Berg, F., Ponta, H., Herrlich, P., Pals, S. T. Activated human lymphocytes and aggressive Non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. *J. Exp. Med.* 177: 897-904 (1993).
- 30

Kreitman R J Hansen H J, Jones A L, FitzGerald D J P, Goldenberg D M, Pastan I. *Pseudomonas* exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. *Cancer Res.* 53: 819-825 (1993).

5

Lambert et al, *Biochem.* 22: 3913-3920 (1983).

Lambert JM, Derr SM, Cook S, Braman G, Widdison W, Chari RVJ. Pharmacokinetics, in vivo stability, and toxicity of the Tumor-activated prodrug, C242-DM1, a novel colorectal cancer agent. *Proceedings of the American Association of Cancer Research* (1998) 39: Abs 3550

10

Liu et al, *Biochem.* 18: 690 (1979), Blakey and Thorpe, *Antibody, Immunoconjugates and Radiopharmaceuticals*, 1: 1-16 (1988).

15

Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blättler WA, Chari RVJ. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. *Proc Natl Acad Sci USA* 93: 8618-23, 1996.

20

Martin S, Jansen F, Bokelmann J, and Kolb H. Soluble CD44 splice variants in metastasizing human breast cancer. *Int J Cancer* 74 (4): 443-445, 1997.

25

Screaton, G.R., Bell, M.V., Jackson, D.G., Cornelis, F.B., Gerth, U., and Bell, J. I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. *Proc. Natl. Acad. Sci. U.S.A.* 89: 12160-12164 (1992).

30

Shin S-U, Morrison S L. Production and properties of chimeric antibody molecules. *Methods Enzymol.* 178: 459-476 (1989).

Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, and Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. *Br.J.Cancer* 72: 1494-1497 (1995).

- Stemmer et al. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides, *Gene* 164(1): 49-53 (1995).
- 5 Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. *Clin Cancer Res* 6 (8):3046-55, 2000
- 10 Tölg, C., Hofmann, M., Herrlich, P., and Ponta, H. Splicing choice from ten variant exons establishes CD44 variability. *Nucleic Acids. Res.* 21: 1225-1229 (1993).
- Tolcher AW et al. SB-408075, a maytansinoid immunoconjugate directed to the C242 antigen: a phase I pharmacokinetic and biologic correlative study. Poster presented at 11th
- 15 Symp. on new drugs in cancer therapy (Nov 7-10, 2000 in Amsterdam).
- Urlaub and Chasin. *Proc. Natl. Acad. Sci. U.S.A.* 77(7): 4216-20 (1980)
- Urlaub et al., *Cell* 33: 405-412 (1983)
- 20 Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, van Dongen GMS. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44v6 in nude mice bearing head-and-neck cancer xenografts. *Int. J. Cancer* 99: 396-402 (2002).
- 25 Winter, G., Griffith, A. D., Hawkins, R. E., Hoogenboom, H. R. Making antibodies by phage display technology. *Ann. Rev. Immunol.* 12: 433-455 (1994).
- Worrell et al, *Anti-Cancer Drug Design* 1: 179-184 (1986).
- 30 Ye et al. Gene synthesis and expression in *E. coli* for pump, a human matrix metalloproteinase. *Biochem Biophys Res Commun* 186(1):143-9 (1992).

Examples

1. Material and Methods

5 1.1. In vitro cell proliferation assay

For determination of viable cells the Cell Titer 96[®] AQueous non-radioactive cell proliferation assay (Promega) was used. 5000 cells per well were seeded into 96-well plates in 90 µl medium without phenole red. Cells were allowed to settle down for 1 to 3 h and then serial dilutions of the immunoconjugate in 10 µl PBS were added. Cells without
10 immunoconjugate served as negative control. Cells were incubated for 4 days at 37°C in a humidified 5% CO₂ atmosphere and then 20 µl MTS/ PMS were added according to the manufacturer's recommendation. After additional 1 to 4 h incubation at 37°C the absorbance at 490 nm was recorded using an ELISA plate reader. For each cell line triplicates were analyzed. The percentage of the surviving cell fraction and the IC50 value
15 were calculated using the GraphPad Prism[®] (Version 3.0) software.

1.2. Manufacturing of BIWI 1

Humanised recombinant antibodies BIWA 4 and BIWA 8 which have binding specificity
20 for an epitope within SEQ ID NO: 1 were linked to the maytansinoid DM1 as described below. The conjugate of BIWA 4 with DM1 was designated BIWI 1.

Generation of stably transfected cell lines. The genes coding for the light and heavy chains of BIWA 4, SEQ ID NO: 5 and SEQ ID NO: 7, were ligated into expression vector
25 pAD-CMV1 (WO92/01055; NCBI GenBank Accession No. A32111) or pAD-CMV19 (NCBI GenBank Accession No. A32110). In the second antibody BIWA 8, the light chain was coded by a gene having SEQ ID NO: 9, while the heavy chain was the same as in BIWA 4. Stably transfected cell lines were generated by electroporation as follows. CHO DUX/57ss (dhfr negative mutant of Chinese Hamster Ovary cells, adapted for serum free
30 suspension culture) were used. After trypsinisation and inactivation of trypsin with RPMI-10 (90% RPMI 1640, 10% heat inactivated fetal calf serum), cells were washed once with RPMI-0 (RPMI 1640 without serum), and 1×10^7 cells were resuspended in 0.8 ml RPMI-0. After addition of the linearised DNA (20 µg per plasmid; cotransfection of vectors coding

for light and heavy chain) the cells were electroporated using a Hoefer Electroporator under the following conditions: 1080 μ F, 320 V, 1000 msec, 1 pulse. Cells were allowed to stand for 5 min, and were then diluted to 12500 cells/ml and 2500 cells/ml in alfa-MEM 10d (90% MEM alfa without ribonucleosides and without desoxyribonucleosides (GIBCO BRL), 10% heat inactivated dialysed fetal calf serum). The cells were seeded into 96 well microtiter plates (200 μ l/well, corresponding to 2500 and 500 cells/well respectively). Clones appeared after 10 days. Only the plates with 500 cells/well were followed up (3-6 clones/well). After 14-15 days, supernatants from each well were tested in a κ/γ ELISA. 53 clones were seeded in 12 well plates in alfa-MEM 10d. After 3-6 days (depending on the confluency of the cells) supernatants were tested again in the κ/γ ELISA (serial dilutions) and quantitated using a human IgG1 standard. Cells were frozen and stored in liquid nitrogen. IgG contents of the 53 clones ranged from 12 - 417 ng/ml. 10 clones with the highest expression level were selected and subcloned as follows: Cells of each clone were seeded into 96 well microtiter plates with densities of 1 and 5 cells/well in 100 μ l/well alfa-MEM 10d (1 plate for each clone and each density). 8 days later supernatants were diluted 1:2 and 100 μ l of this dilution tested in the κ/γ ELISA and quantitated using a BIWA 4 preparation as standard. 5 subclones of each clone were transferred to 12 well plates. The IgG content ranged from 1.3 - 908 ng/ml. 14 clones with the highest expression level (384 - 908 ng/ml) were used for amplification with methotrexate as follows: Clones were initially cultured in 25 cm² flasks containing alfa-MEM 10d with 20, 50 and 100 nM methotrexate. After the outgrowth of clones the supernatants were tested in the κ/γ ELISA. In subsequent rounds of amplification the methotrexate concentration was raised up to 2000 nM. Initially the highest expression level ranged from 10.5-14.8 μ g/ml (clone A31/100, 100 nM methotrexate). Further amplification with a methotrexate concentration of 500 nM gave an expression of 19-20 μ g/ml (A31/500).

Purification of antibody. Antibody was purified from cell culture supernatant as follows. Antibody containing tissue culture supernatant was applied onto a 5 ml protein A sepharose column with a flow rate of 80-90 ml/h at 4 °C. After washing with 50 ml binding buffer (0.1 M sodium phosphate pH 7.5), the Ig fraction was eluted with elution buffer (0.1 M glycine-HCl pH 2.7). Absorption at 280 nm was monitored.

Modification of BIWA 4 with SPP to form BIWA 4-SS-Py. BIWA 4 was supplied in liquid form at a concentration of 5 mg/mL in a PBS formulation containing Tween 20. Prior to coupling of DM1 to the MAb the Tween 20 was removed. The MAb solution (40 mL) was diluted 15-fold with 25 mM MES buffer, pH 5.6, containing 50 mM NaCl (MES buffer) and then loaded onto a column (12.5 mL) of Sepharose S equilibrated in MES buffer (flow rate: 100 cm/hr). The column was washed with 10 column volumes of MES buffer. The antibody was eluted with MES buffer containing 400 mM NaCl. The antibody solution was dialysed against 50 mM potassium phosphate buffer, pH 6.5 containing 50 mM NaCl and 2 mM EDTA (Buffer A). The BIWA 4 antibody was modified using SPP ((2-Pyridyl)-5-dithiopentanoic acid N-hydroxy succinimid ester) to introduce dithiopyridyl groups. The MAb in Buffer A (185 mg, 8 mg/mL) was modified with a 7-fold molar excess of SPP in EtOH (5% v/v of MAb solution). The reaction proceeded for 90 minutes at ambient temperature. The reaction mixture was then subjected to gel filtration chromatography through Sephadex G25F (2.6 x 31.5 cm column, 167 mL) equilibrated in Buffer A. MAb-containing fractions were pooled and the degree of modification was determined by measuring the absorbance at 280 nm and the change in absorbance at 343 nm caused by the release of 2-mercaptopyridine by the addition of DTT. The concentration of released 2-mercaptopyridine was calculated using an $\epsilon_{343 \text{ nm}}$ of $8080 \text{ M}^{-1}\text{cm}^{-1}$, and the concentration of MAb was calculated using an $\epsilon_{280 \text{ nm}}$ of $224,000 \text{ M}^{-1}\text{cm}^{-1}$ after the absorbance at 280 nm has been corrected for the contribution from 2-mercaptopyridine. (2-mercaptopyridine $A_{280 \text{ nm}} = A_{343 \text{ nm}} \times 5100/8080$). Recovery of the MAb was 99.6% with 5.5 releasable 2-mercaptopyridine groups linked per MAb molecule.

Conjugation of BIWA 4-SS-Py with DM1. The above modified MAb (184 mg) in Buffer A was conjugated at 2.5 mg MAb/mL using a 1.7-fold molar excess of DM1 over releasable 2-mercaptopyridine groups. DM1 was added in DMA (3% v/v of MAb solution) and the reaction mixture was incubated at ambient temperature for 29 hours. The conjugate was then isolated by gel filtration chromatography on a column of Sephacryl S300 HR equilibrated in PBS (5 x 50 cm column, 980 mL, flow rate of 10 cm/hr). The conjugate eluted as a single peak at the position of monomeric MAb with a small amount of protein eluting earlier. Fractions were assayed for the number of DM1 molecules linked per MAb molecule. (Linked DM1 molecules were determined by measuring the absorbance at both 252 nm and 280 nm). Based on the results, fractions representing 63-77% of the

column volume were pooled. The DM1/MAB ratio in the pooled solution was found to be 3.1 and the yield of conjugated BIWA 4 was 75% based on starting MAB. The conjugate, BIWI 1, was evaluated by SDS-PAGE performed under non-reducing conditions and found to be composed primarily of a monomer species (>95%) with a minor amount (<5%) of dimeric conjugate.

Analysis of *in vitro* binding of BIWI 1. The binding of BIWA 4 antibody and BIWI 1 conjugate to antigen-positive FaDu cells was determined. Cells ($1-2 \times 10^5$) were incubated in 96-well plates with varying concentrations of antibody or conjugate on ice for 1 hour. The test article was washed from the plate and FITC-labeled anti-human IgG was added and the incubation on ice was continued in the dark for 1 hour. After washing, the cells were fixed with 1% paraformaldehyde and analyzed on a fluorescence activated cell sorter (FACS). BIWA 4 antibody binds with an apparent K_D of 1×10^{-9} M and BIWI 1 binds with an apparent K_D of 1.8×10^{-9} M. Thus, conjugation with DM1 alters the binding affinity of the antibody only slightly if at all.

1.3. Efficacy studies in nude mice

In vivo anti-tumor efficacy of BIWI 1 was tested in two nude mouse xenograft models applying antigen-positive human tumors, which differed in tumor origin, extent and homogeneity of CD44v6 expression: A431 (ATCC # CRL 1555; epidermoid carcinoma of the vulva), FaDu (ATCC # HTB 43; squamous cell carcinoma of the pharynx). Tumor cell lines A431 and FaDu were received from ATCC and cultured in RPMI1640 medium containing 10% fetal calf serum and supplements.

Mice were randomised into the following treatment groups (treatment/initial mean tumour volume/tumour volume range/number of mice):

A431

- | | |
|----------|---|
| Group 1: | Control (PBS) / $185 \pm 217 \text{ mm}^3$ / 19 – 424 mm^3 / 5 mice. |
| Group 2: | BIWA 4 (21 mg/kg/d) / $133 \pm 115 \text{ mm}^3$ / 42 – 302 mm^3 / 5 mice. |
| Group 3: | BIWI 1 (2.1 mg/kg/d) / $107 \pm 63 \text{ mm}^3$ / 42 – 205 mm^3 / 5 mice. |

Group 4: BIWI 1 (7 mg/kg/d) / $132 \pm 73 \text{ mm}^3$ / 42 – 205 mm^3 / 5 mice.

Group 5: BIWI 1 (21 mg/kg/d) / $107 \pm 63 \text{ mm}^3$ / 42 – 205 mm^3 / 5 mice.

FaDu

5 Group 1: Control (PBS) / $142 \pm 82 \text{ mm}^3$ / 34 – 268 mm^3 / 8 mice.

Group 2: BIWA 4 (21 mg/kg/d) / $134 \pm 86 \text{ mm}^3$ / 42 – 268 mm^3 / 6 mice.

Group 3: BIWI 1 (2.1 mg/kg/d) / $149 \pm 96 \text{ mm}^3$ / 50 – 268 mm^3 / 6 mice.

Group 4: BIWI 1 (7 mg/kg/d) / $132 \pm 97 \text{ mm}^3$ / 42 – 268 mm^3 / 6 mice.

Group 5: BIWI 1 (21 mg/kg/d) / $129 \pm 74 \text{ mm}^3$ / 50 – 231 mm^3 / 6 mice.

10

1×10^6 tumors cells were transplanted subcutaneously into the right flank of 6 week old female NMRI-nu/nu mice. Treatment started when the tumors reached an average size of 107 to 185 mm^3 . Treatment consisted of i.v. injections of BIWI 1 given on five consecutive days, starting at day 1. 3 different doses of BIWI 1 were tested in parallel: 2.1 mg/kg/d BIWI 1 corresponding to 30 $\mu\text{g/kg/d}$ DM1, 7 mg/kg/d BIWI 1 corresponding to 100 $\mu\text{g/kg/d}$ DM1, and 21 mg/kg/d BIWI 1 corresponding to 300 $\mu\text{g/kg/d}$ DM1. Control animals were either untreated (PBS) or treated with unconjugated antibody (control antibody, 21 mg/kg/d). Tumor growth was monitored by measuring tumor size. A tumor response was rated as complete response when the tumor completely disappeared at any time after start of treatment. The response was rated as partial response when the tumor volume decreased after treatment but thereafter started regrowing. The tolerability of the treatment was monitored by measuring mouse weight during the whole observation period.

25 2. Results and Discussion

2.1. *In vitro* cytotoxicity of BIWI 1

The *in vitro* cytotoxicity of BIWI 1 was evaluated using the antigen-positive cell lines A431 and FaDu, and the antigen-negative cell line A459. Cells were exposed to different concentrations of BIWI 1 for 4 days, then stained with MTS/ PMS and assayed on an ELISA plate reader. The surviving fractions of cells were then calculated using the GraphPad Prism[®] software package. The results are shown in Figure 1. BIWI 1 was

30

effective in killing the antigen-positive A431 cells with an IC_{50} of about 7.6×10^{-8} M and the second antigen-positive cell line, FaDu, with an IC_{50} of about 2.4×10^{-8} M. The antigen-negative cell line, A549, was effected by the conjugate with an IC_{50} of about 1.3×10^{-7} M with a surviving fraction of 50% at the highest concentration of BIWI 1 tested (5×10^{-7} M). These results show that BIWI 1 is only slightly more cytotoxic against antigen-positive cells than antigen-negative cells *in vitro*. For comparison, another DM1-antibody conjugate has been shown to be at least 1000fold more cytotoxic against antigen-positive cell as compared to antigen-negative cells (Chari *et al.*, 1992).

2.2. Efficacy in A431 xenografted nude mice

Groups of 5 mice were treated with 2.1 mg/kg/d BIWI 1, 7 mg/kg/d BIWI 1, 21 mg/kg/d BIWI 1, and 21 mg/kg/d control antibody, respectively. The average tumor size at start of treatment was $185 \pm 217 \text{ mm}^3$ (PBS), $133 \pm 115 \text{ mm}^3$ (control antibody), $107 \pm 63 \text{ mm}^3$ (21 mg/kg/d BIWI 1), $132 \pm 73 \text{ mm}^3$ (7 mg/kg/d BIWI 1), and $107 \pm 63 \text{ mm}^3$ (2.1 mg/kg/d BIWI 1), respectively. The average tumor volume of each group during the observation period is shown in Figure 2. Tumors treated with control antibody showed similar growth as untreated tumors, the tumor volume doubling time was approximately 5 days. In animals treated either with 7 mg/kg/d BIWI 1 or 21 mg/kg/d BIWI 1 all tumors responded completely and disappeared around day 17. No tumor regrowth was observed until the end of the observation period (day 134). Tumors treated with 2.1 mg/kg/d responded completely in 3/5 cases with no tumor regrowth until day 134. The remaining 2 tumors showed a partial response but ultimately regrew. These results show that BIWI 1 induces a dose-dependent anti-tumor response in A431 xenografted nude mice, with complete and long-lasting responses from 2.1 mg/kg/d BIWI 1 to 21 mg/kg/d BIWI 1. Unconjugated control antibody shows no anti-tumor effect.

See Figure 2.

2.2. Efficacy in FaDu xenografted nude mice

Groups of 6 mice were treated with 2.1 mg/kg/d BIWI 1, 7 mg/kg/d BIWI 1, 21 mg/kg/d BIWI 1, and 21 mg/kg/d control antibody, respectively. The average tumor size at start of treatment was 142 +/- 82 mm³ (PBS), 134 +/- 86 mm³ (control antibody), 129 +/- 74 mm³ (21 mg/kg/d BIWI 1), 132 +/- 97 mm³ (7 mg/kg/d BIWI 1), and 149 +/- 96 mm³ (2.1 mg/kg/d BIWI 1), respectively. The average tumor volume of each group during the observation period is shown in Figure 3. Tumors treated with control antibody and 2.1 mg/kg/d BIWI 1 showed similar growth as untreated tumors, the tumor volume doubling time was approximately 5 days. In animals treated with 21 mg/kg/d BIWI 1 all tumors responded completely and disappeared around day 24. No tumor regrowth was observed until the end of the observation period (day 107). 1/6 tumors treated with 7 mg/kg/d BIWI 1 responded completely, 3/6 tumors showed partial responses. The remaining 2 tumors grew similar to untreated control tumors. These results show that BIWI 1 induces a dose-dependent anti-tumor response in FaDu xenografted nude mice, with complete and long-lasting responses from 7 mg/kg/d BIWI 1 to 21 mg/kg/d BIWI 1. Unconjugated control antibody shows no anti-tumor effect.

See Figure 3.

2.4. Tolerability in nude mice

The tolerability of BIWI 1 treatment was determined by monitoring mouse weight during the whole duration of the experiment in the 2 models. The maximum observed average weight loss per group was 5% in FaDu xenografted mice treated with 21 mg/kg/d BIWI 1 (Figure 4). The weight loss started around day 3 of treatment and lasted until day 10, thereafter animals regained weight and behaved similar as control animals. In all other dose groups weight loss was similar to vehicle control (PBS). An average weight loss of 5% or less in all treatment groups indicates good tolerability of BIWI 1 treatment at the given doses in nude mice. As BIWI 1 does not cross-react with mouse CD44v6, only antigen-independent effects such as toxicity caused by free DM1 can be monitored in this experiment.

3. *In vivo* anti-tumor efficacy in MDA-MB 453

3.1. Material and Methods

5 *In vivo* anti-tumor efficacy of BIWI 1 was tested in a nude mouse xenograft model applying the antigen-positive human tumor MDA-MB 453 (ATCC # HTB-131; breast carcinoma). The cells were received from ATCC and cultured in RPMI1640 medium containing 10% fetal calf serum and supplements. 1×10^6 tumors cells were transplanted subcutaneously into the right flank of 6 week old female NMRI-nu/nu mice. For therapy
10 experiments tumors were maintained via passaging of tumor fragments. Treatment started when the tumors reached an average size of 188 to 246 mm³. Treatment consisted of i.v. injections of BIWI 1 given weekly for four weeks. 3 different doses of BIWI 1 were tested in parallel: 6.25 mg/kg BIWI 1 corresponding to 100 µg/kg DM1, 12.5 mg/kg BIWI 1 corresponding to 200 µg/kg DM1, and 25 mg/kg BIWI 1 corresponding to 400 µg/kg DM1.
15 PBS treated animals served as tumor growth control. Tumor growth was monitored by measuring tumor size. A tumor response was rated as complete response when the tumor completely disappeared at any time after start of treatment.

3.2. Results and Discussion

20 Groups of 6 mice were treated with 6.25 mg/kg BIWI 1, 12.5 mg/kg BIWI 1, and 25 mg/kg BIWI 1, respectively, once a week for four weeks. The average tumor size at start of treatment was 246 +/- 79 mm³ (PBS), 216 +/- 85 mm³ (6.25 mg/kg BIWI 1), 188 +/- 79 mm³ (12.5 mg/kg BIWI 1), and 207 +/- 96 mm³ (25 mg/kg BIWI 1), respectively. The
25 average tumor volume of each group during the observation period is shown in Figure 5. The initial tumor volume doubling time of the control tumors was approximately 5 days. In animals treated with 25 mg/kg BIWI 1 all tumors responded completely and disappeared around day 22 after start of treatment. No tumor regrowth was observed until the end of the observation period (day 64). Tumors treated with 12.5 mg/kg or 6.25 mg/kg responded
30 completely in 5/6 cases in each dose group, and 4 animals of each group stayed tumor free until the end of the experiment. These results show that BIWI 1 induces excellent anti-tumor responses in MDA-MB 453 xenografted nude mice when given once a week over a

period of four weeks, with complete and long-lasting responses from 6.25 mg/kg BIWI 1 to 25 mg/kg BIWI 1.

5

Figures

Figure 1: in vitro cytotoxicity of BIWI 1. The antigen-positive cell lines A431 and FaDu and the antigen-negative cell line A549 were used.

10 **Figure 2:** Efficacy of BIWI 1 treatment in nude mice xenografted with A431 tumors. The average tumor volumes per group with standard deviations are shown, the treatment groups are indicated. The arrow indicates start of treatment (day 1).

15 **Figure 3:** Efficacy of BIWI 1 treatment in nude mice xenografted with FaDu tumors. The average tumor volumes per group with standard deviations are shown, the treatment groups are indicated. The arrow indicates start of treatment (day 1).

Figure 4: Tolerability of BIWI 1 treatment. The average body weight change of all treatment groups in the 2 investigated models is shown. Day 1: start of treatment.


20

Figure 5: Efficacy of BIWI 1 treatment in nude mice xenografted with MDA-MB 453 tumors. The average tumor volumes per group with standard deviations are shown, the treatment groups are indicated. The arrows indicate the treatment days .

25

Claims

1. A compound of formula
 $A(LB)_n$
5 wherein
A is an antibody molecule which is specific for CD44;
L is a linker moiety;
B is a compound which is toxic to cells; and
n is an decimal number with $n = 1$ to 10.
10
2. The compound of claim 1 wherein said linker moiety has a chemical bond capable of being cleaved inside a cell.
3. The compound of claim 2 wherein said chemical bond is a disulfide bond.
15
4. The compound of claims 1 to 3, wherein the antibody molecule is specific for the exon v6 of human CD44.
5. The compound of claims 1 to 4, wherein the antibody molecule is specific for an
20 epitope within the amino acid sequence SEQ ID NO: 3.
6. The compound of claims 1 to 5, wherein the antibody molecule is the monoclonal antibody VFF-18 (DSM ACC2174) or a recombinant antibody having the complementary determining regions (CDRs) of VFF-18.
25
7. The compound of claims 1 to 6, wherein the antibody molecule comprises light chains having the amino acid sequence SEQ ID NO: 4, or SEQ ID NO: 8, and heavy chains having the amino acid sequence SEQ ID NO: 6.
- 30 8. The compound of claims 1 to 7, wherein the toxic compound B is a maytansinoid.
9. The compound of claim 8 wherein the maytansinoid has the formula



(Formula (II))

wherein

R_1 represents H or SR_4 , wherein R_4 represents methyl, ethyl, linear alkyl, branched
5 alkyl, cyclic alkyl, simple or substituted aryl, or heterocyclic;


R_2 represents Cl or H;

R_3 represents H or CH_3 ; and

m represents 1, 2, or 3.

10 10. The compound of claim 9, wherein R_1 is H or CH_3 , R_2 is Cl, R_3 is CH_3 , and $m = 2$.

11. The compound of claims 1 to 10 of formula



(Formula III)

wherein


A is an antibody molecule which is specific for CD44,

(L') is an optional linker moiety

p is a decimal number with $p = 1$ to 10 .


12. The compound of claims 1 to 11 wherein p is 3 to 4.
- 5 13. A conjugate of a CD44v6 specific antibody molecule and a maytansinoid.
14. The conjugate of claim 13, wherein the antibody molecule is specific for an epitope within the amino acid sequence SEQ ID NO: 3.
- 10 15. The conjugate of claim 14, wherein the antibody molecule is the monoclonal antibody VFF-18 (DSM ACC2174) or a recombinant antibody having the complementary determining regions (CDRs) of VFF-18.

16. The conjugate of any one of claims 13 to 15, wherein said antibody molecule comprises light chains having the amino acid sequence SEQ ID NO: 4, or SEQ ID NO: 8, and heavy chains having the amino acid sequence SEQ ID NO: 6.
- 5 17. The conjugate of any one of claims 13 to 16, wherein the maytansinoid is linked to the antibody molecule by a disulfide moiety.
18. The conjugate of any one of claims 13 to 17, wherein the maytansinoid has the formula



10 Formula (IV)

19. A conjugate of a CD44v6 specific antibody molecule and a maytansinoid, wherein the antibody comprises light chains having the amino acid sequence SEQ ID NO: 4, and heavy chains having the amino acid sequence SEQ ID NO: 6, and wherein the
- 15 maytansinoid has the formula



(Formula IV)

and is linked to the antibody through a disulfide bond.

- 5 20. The conjugate of any one of claims 13 to 19, wherein one or more maytansinoid residues are linked to an antibody molecule.
21. The conjugate of claim 20, wherein 3 to 4 maytansinoid residues are linked to an antibody molecule.
- 10 22. The conjugate of any one of claims 13 to 21, wherein the maytansinoid is linked to the antibody molecule through a $-S-CH_2CH_2-CO-$, a $-S-CH_2CH_2CH_2CH_2-CO-$, or a $-S-CH(CH_3)CH_2CH_2-CO-$ group.
- 15 23. Method of production of a compound $A(LB)_n$ according to claims 1 to 12, or a conjugate according to claims 13 to 22, comprising the steps:
 - (a) introducing one or more free or protected thiol groups into an antibody molecule which is specific for CD44;
 - 20 (b) reacting the antibody molecule of step (a) with a compound which is toxic to cells,

said compound having one or more disulfide or thiol groups; and


(c) recovering the resulting conjugate.

24. The method of claim 23, wherein the antibody molecule is specific for CD44v6.

25. The method of claim 24, wherein the antibody molecule is specific for an epitope within SEQ ID NO: 3.

26. The method of any one of claims 23 to 25, wherein the toxic compound is a maytansinoid.

27. The method of claim 26, wherein the maytansinoid has the formula



(Formula II)

wherein

R_1 represents H or SR_4 , wherein R_4 represents methyl, ethyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl, or heterocyclic;

R_2 represents Cl or H;

R_3 represents H or CH_3 ; and

m represents 1, 2, or 3.

28. The method of claim 27, wherein R_1 is H or CH_3 , R_2 is Cl, R_3 is CH_3 , and $m = 2$.

5 29. The method of any one of claims 23 to 28, wherein (2-pyridyl)-3-dithiopropionic acid N-hydroxy succinimid ester, (2-pyridyl)-4-dithiopentanoic acid N-hydroxy succinimid ester, or (2-pyridyl)-5-dithiopentanoic acid N-hydroxy succinimid ester is used to introduce the free or protected thiol groups into the antibody molecule.

10 30. Compound obtainable by a method according to any one of claims 23 to 29.

31. Pharmaceutical composition comprising a compound $A(LB)_n$ according to claims 1 to 12, or 30, or a conjugate according to claims 13 to 22, and a pharmaceutically acceptable carrier, diluent, or excipient.

15

32. Use of a compound $A(LB)_n$ according to claims 1 to 12, or 30, or a conjugate according to claims 13 to 22, for the preparation of a pharmaceutical composition for the treatment of cancer.

20 33. The use of claim 32, wherein the cancer is head and neck squamous cell carcinoma, esophagus squamous cell carcinoma, lung squamous cell carcinoma, skin squamous cell carcinoma, cervix squamous cell carcinoma, breast adenocarcinoma, lung adenocarcinoma, pancreas adenocarcinoma, colon adenocarcinoma, or stomach adenocarcinoma.

25

34. Use of a compound $A(LB)_n$ according to claims 1 to 12, or 30, or a conjugate according to claims 13 to 22, or of a pharmaceutical composition according to claim 31, for the treatment of cancer.

30 35. The use according to claim 34, wherein the cancer is head and neck squamous cell carcinoma, esophagus squamous cell carcinoma, lung squamous cell carcinoma, skin squamous cell carcinoma, cervix squamous cell carcinoma, breast adenocarcinoma,

lung adenocarcinoma, pancreas adenocarcinoma, colon adenocarcinoma, or stomach adenocarcinoma.

36. Method of treatment of cancer in a patient in need thereof comprising administering to
5 the patient a therapeutically effective amount of a compound **A(LB)_n** according to any one of claims 1 to 12, or 30, or a conjugate according to claims 13 to 22, or a pharmaceutical composition according to claim 31.

37. The method of claim 36, wherein the cancer is head and neck squameous cell
10 carcinoma, esophagus squameous cell carcinoma, lung squameous cell carcinoma, skin squameous cell carcinoma, cervix squameous cell carcinoma, breast adenocarcinoma, lung adenocarcinoma, pancreas adenocarcinoma, colon adenocarcinoma, or stomach adenocarcinoma.




Figure 1




Figure 2






Figure 3

**Figure 4**

**Figure 5**

SEQUENCE LISTING

<110> Boehringer Ingelheim International GmbH
 5 <120> Cytotoxic CD44 Antibody Immunoconjugates
 <130>
 <140>
 10 <141>
 <160> 7
 <170> PatentIn Ver. 2.1
 15 <210> 1
 <211> 42
 <212> PRT
 <213> Homo sapiens
 20 <223> Description of Artificial Sequence: Human CD44 Exon v6 SEQ ID
 NO: 1
 <400> 1
 25 Gln Ala Thr Pro Ser Ser Thr Thr Glu Glu Thr Ala Thr Gln Lys Glu
 1 5 10 15
 Gln Trp Phe Gly Asn Arg Trp His Glu Gly Tyr Arg Gln Thr Pro Arg
 20 25 30
 30 Glu Asp Ser His Ser Thr Thr Gly Thr Ala
 35 40
 35 <210> 2
 <211> 14
 <212> PRT
 <213> Homo sapiens
 40 <223> Description of Artificial Sequence: SEQ ID NO: 2
 <400> 2
 Gln Trp Phe Gly Asn Arg Trp His Glu Gly Tyr Arg Gln Thr
 1 5 10
 45 <210> 3
 <211> 11
 <212> PRT
 50 <213> Homo sapiens
 <223> Description of Artificial Sequence: SEQ ID NO: 3
 <400> 3
 55 Trp Phe Gly Asn Arg Trp His Glu Gly Tyr Arg
 1 5 10

<210> 4
 <211> 213
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence: Humanised
 Murine Antibody BIWA 4 Light Chain SEQ ID NO: 4

10

<400> 4
 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

15

Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Ile Asn Tyr Ile
 20 25 30

Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr
 35 40 45

20

Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
 50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
 65 70 75 80

25

Asp Phe Ala Val Tyr Tyr Cys Leu Gln Trp Ser Ser Asn Pro Leu Thr
 85 90 95

30

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro
 100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
 115 120 125

35

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
 130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
 145 150 155 160

40

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 165 170 175

45

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
 180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 195 200 205

50

Asn Arg Gly Glu Cys
 210

55

<210> 5
 <211> 702
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised

Murine Antibody BIWA 4 Light Chain SEQ ID NO: 5

5 <400> 5
 atggaagccc cagctcagct tctcttctc ctgctgctct ggctcccaga taccaccgga 60
 gaaattgttc tcaccagtc tccagcaacc ctgtctctgt ctccagggga gagggccacc 120
 ctgtcctgca gtgccagctc aagtataaat tacatatact ggtaccagca gaagccagga 180
 caggctccta gactcttgat ttatctcaca tccaacctgg cttctggagt ccctgcgcgc 240
 10 ttcagtggca gtgggtctgg aaccgacttc actctcacia tcagcagcct ggagcctgaa 300
 gattttgccc tttattactg cctgcagtgg agtagtaacc cgctcacatt cgggtggtggg 360
 accaagggtg agattaaacg tacgggtggc gcaccatctg tcttcatctt cccgccatct 420
 gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 480
 agagaggcca aagtacagtg gaagggtgat aacgccctcc aatcgggtaa ctcccaggag 540
 15 agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 600
 agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 660
 agctcgcccc tcacaaagag cttcaacagg ggagagtgtt ga 702

20 <210> 6

<211> 444

<212> PRT

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: Humanised

Murine Antibody BIWA 4 Heavy Chain SEQ ID NO: 6

<400> 6
 30 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 35 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Leu Asp Ser Ile
 40 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 45 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gln Gly Leu Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val
 100 105 110
 50 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
 115 120 125
 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
 55 130 135 140
 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
 145 150 155 160

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
 165 170 175
 5 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
 180 185 190
 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
 195 200 205
 10 Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
 210 215 220
 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
 15 225 230 235 240
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 245 250 255
 20 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 260 265 270
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 275 280 285
 25 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 290 295 300
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 30 305 310 315 320
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 325 330 335
 35 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 340 345 350
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 355 360 365
 40 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 370 375 380
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 45 385 390 395 400
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 405 410 415
 50 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 420 425 430
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440
 55
 <210> 7
 <211> 1392

<212> DNA

<213> Artificial Sequence

<220>

- 5 <223> Description of Artificial Sequence: Humanised
Murine Antibody BIWA 4 Heavy Chain SEQ ID NO: 7

<400> 7

```

atggagtttg ggctgagctg gctttttctt gtggctatatt taaaagggtgt ccagtgtgaa 60
10 gtgcagctgg tggagtctgg gggaggctta gtgaagcctg gaggggccct aagactctcc 120
tgtgcagcct ctggattcac ttccagtacg tatgacatgt cttgggttcg ccaggctccg 180
gggaaggggc tggagtgggt ctcaaccatt agtagtggtg gtagttacac ctactatcta 240
gacagtataa agggccgatt caccatctcc agagacaatg ccaagaactc cctgtacctg 300
caaatgaaca gtctgagggc tgaggacacg gccgtgtatt actgtgcaag acagggggtg 360
15 gactactggg gtcgaggaac cttagtcacc gtctcctcag ctagcaccaa gggcccatcg 420
gtcttcccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc 480
ctgggtcaagg actacttccc cgaaccgggt acgggtgtcg ggaactcagg cgccctgacc 540
agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc 600
gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac 660
20 aagcccagca acaccaaggt ggacaagaaa gttgagccca aatcttgtga caaaactcac 720
acatgccac cgtgccacg acctgaactc ctggggggac cgtcagtcct cctcttcccc 780
ccaaaaccca aggacaccct catgatctcc cggaccctcg aggtcacatg cgtgggtggtg 840
gacgtgagcc acgaagaccc tgaggtcaag ttcaactggg acgtggacgg cgtggaggtg 900
cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc 960
25 gtcctcaccc tccctgcacca ggactggctg aatggcaagg agtacaagtg caaggctctc 1020
aacaagccc tccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga 1080
gaaccacagg tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc 1140
ctgacctgcc tgggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 1200
gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260
30 ttctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 1320
tgctccgtga tgcattgagg tctgcacaac cactacacgc agaagagcct ctccctgtct 1380
ccgggtaaat ga 1392

```

35

<210> 8

<211> 213

<212> PRT

<213> Artificial Sequence

40

<220>

- <223> Description of Artificial Sequence: Humanised
Murine Antibody BIWA 8 Light Chain SEQ ID NO: 8

45

<400> 8

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
  1                      5                      10                      15

Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Ile Asn Tyr Ile
50          20          25          30

Tyr Trp Leu Gln Gln Lys Pro Gly Gln Ala Pro Arg Ile Leu Ile Tyr
          35          40          45

Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
55          50          55          60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu

```

